All In Biotech

Drug Trial Radar · NCT07839871

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 920 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

920

Planned (sponsor's estimate)

Start

Sep 22, 2026

Primary completion

Mar 30, 2031

Study completion Mar 30, 2031

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to \<18 years of age at high risk for RSV disease, including those who are immunocompromised.

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • RSVpreFBiological

    RSVpreF Vaccine

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Proportion of participants reporting pre-specified local reactions within 7 days following investigational product administrationTime frame: Within 7 days
  2. Cohort 2: Proportion of participants reporting pre-specified local reactions within 7 days following each investigational product administrationTime frame: Within 7 days
  3. Cohort 1: Proportion of participants reporting pre-specified systemic events within 7 days following investigational product administrationTime frame: Within 7 days
  4. Cohort 2: Proportion of participants reporting pre-specified systemic events within 7 days following each investigational product administrationTime frame: Within 7 days
  5. Cohort 1: Proportion of participants reporting adverse events (AEs) through 1 month following investigational product administrationTime frame: From vaccination through 1 month after vaccination
  6. Cohort 2: Proportion of participants reporting adverse events (AEs) through 1 month following last investigational product administrationTime frame: From vaccination through 1 month after last vaccination
  7. Cohort 1: Proportion of participants reporting serious adverse events (SAEs) throughout the studyTime frame: From vaccination through 24 months after vaccination
  8. Cohort 2: Proportion of participants reporting serious adverse events (SAEs) throughout the studyTime frame: From vaccination through 12 months after last vaccination
  9. Cohort 1: Proportion of participants reporting newly diagnosed chronic medical conditions (NDCMCs) throughout the studyTime frame: From vaccination through 24 months after vaccination
  10. Cohort 2: Proportion of participants reporting newly diagnosed chronic medical conditions (NDCMCs) throughout the studyTime frame: From vaccination through 12 months after last vaccination
  11. Cohort 1: Geometric mean ratio (GMR), estimated by the ratio of the geometric mean titers (GMTs) for RSV A and RSV B serum neutralizing titers (NTs) 1 month after vaccination in participants in Study C3671017 Cohort 1 compared to those in Study C3671013Time frame: 1 month after vaccination
  12. Cohort 1: Seroresponse rate of RSV A and RSV B serum NTs at 1 month after vaccinationTime frame: 1 month after vaccination
  13. Cohort 2: Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)Time frame: Before each vaccination, 1 month after each vaccination, 12 months after last vaccination
  14. Cohort 2: NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)Time frame: 1 month after each vaccination, 12 months after last vaccination
  15. Cohort 2: NTs for RSV A and RSV B expressed as seroresponse rateTime frame: 1 month after each vaccination, 12 months after last vaccination

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Duke Vaccine and Trials Unit

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center Vaccine Research Center

    Cincinnati, Ohio · Recruiting

  • Senders Pediatrics

    South Euclid, Ohio · Recruiting

  • Seattle Childrens Research Institute

    Seattle, Washington · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Maebashi Red Cross Hospital

    Maebashi, Gunma, Japan · Recruiting

  • Saitama City Hospital

    Midori, Saitama, Japan · Recruiting

  • Fukuwa Clinic

    Chuo-ku, Tokyo, Japan · Recruiting

  • Uniwersytecki Dziecięcy Szpital Kliniczny im. L. Zamenhofa w Białymstoku

    Bialystok, Poland · Not yet recruiting

  • IN-VIVO Bydgoszcz

    Bydgoszcz, Poland · Not yet recruiting

  • Samodzielny Zespół Publiczny Zakładów Opieki Zdrowotnej im. Dzieci Warszawy w Dziekanowie Leśnym

    Dziekanów Leśny, Poland · Recruiting

  • Pro Familia Altera Sp. z o.o.

    Katowice, Poland · Not yet recruiting

  • Centrum Badań Klinicznych - Jagiellońskie Centrum Innowacji Sp. z o.o.

    Krakow, Poland · Recruiting

  • ALERGO-MED Osrodek Badan Klinicznych Sp z o.o.

    Tarnów, Poland · Not yet recruiting

  • Szpital im.Sw.Jadwigi Slaskiej w Trzebnicy

    Trzebnica, Poland · Not yet recruiting

  • ZOZ Medyk Sp. z o.o.

    Milówka, Silesian Voivodeship, Poland · Not yet recruiting

  • Servicio Andaluz de Salud (SAS) - Hospital de Antequera

    Antequera, Spain · Not yet recruiting

  • Hospital Universitario HM Puerta del Sur

    Móstoles, Spain · Not yet recruiting

  • Instituto Hispalense de Pediatria

    Seville, Spain · Not yet recruiting

  • Hospital Universitario La Paz

    Madrid, Madrid, Comunidad de, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.